One failed trial. $20 billion gone. And suddenly, the market's asking if AstraZeneca's golden run is cracking.
For 14 years, CEO Pascal Soriot could do no wrong.
Shares up 4x. Beating GSK. Beating the FTSE 100. Analysts called it his Midas touch.
Then, on July 9, that touch wobbled.
Here's what happened.
Wainua — a nerve drug already approved for a rare disorder — was being tested as a heart disease treatment.
It failed.
Not a small stumble either.
This wasn't Wainua's first stumble in the spotlight either.
Back in May, a US regulatory panel had already rejected AstraZeneca's breast cancer drug camizestrant over trial design issues.
Two blows in three months.
That's when "one-off" starts sounding less convincing.
Not so fast, say some analysts.
Jefferies called the share slide a "significant overreaction" — AstraZeneca still has roughly 200 assets in late-stage development.
But others aren't as calm.
HSBC's Rajesh Kumar downgraded the stock from buy to hold, saying: "Do I feel confident investing right now? No, I don't."
AstraZeneca reports earnings this Monday.
Nobody's watching the revenue line.
Everyone's watching two words: SERENA-4 and AVANZAR.
These are AstraZeneca's next big oncology trials — breast cancer and lung cancer respectively.
Why do they matter so much?
Because AstraZeneca has bet its future on hitting $80 billion in annual revenue by 2030, up from $59 billion last year — built on roughly 20 new drug launches.
Fail both trials, and it's three misses out of three this year.
That's the kind of pattern that makes investors question not just luck, but strategy.
Fund manager Markus Manns put it bluntly — expect scrutiny on trial design, pipeline choices, even pressure for AstraZeneca to go shopping for acquisitions.
Succeed, and this Wainua wobble becomes a footnote in an otherwise unbroken winning streak.
Either way, Monday isn't just an earnings call.
It's a verdict on whether the Midas touch still holds.
That's all for now!
